Institute of Microelectronics, A⁎STAR (Agency for Science, Technology and Research), 11 Science Park Road, Singapore Science Park II, 117685 Singapore.
Department of Hematology-Oncology, National University Cancer Institute of Singapore, Singapore; National University Health System, Singapore; Cancer Science Institute of Singapore, Singapore; National University of Singapore, Singapore.
Biosens Bioelectron. 2015 Dec 15;74:865-71. doi: 10.1016/j.bios.2015.07.055. Epub 2015 Jul 26.
Epidermal growth factor receptor (EGFR) is a non-small-cell lung cancer biomarker, based on which several near-patient-testing methods have been developed and applied to predict treatment response on individual patients. Existing methods for detection of EGFR mutation are costly, labor-intensive and time-consuming. In this paper, we report a novel EGFR mutation testing system, which is based on Mach-Zehnder Interferometer (MZI) sensor and isothermal solid-phase DNA amplification (IDA) technique, called MZI-IDA sensor system. The system can deliver results within 30 min and shows high sensitivity to detect trace amounts of genomic DNA (<1 copy). In addition, the system is able to detect a L858R mutation in a 99:1 mixture of wild-type and mutant cells. In a pilot clinical study, the system is compared with conventional methods (PCR and direct sequencing) by using tissue biopsy samples from NSCLC patients. The MZI-IDA sensor system is proved to be capable of fast and accurate detection of the L858R mutation of EGFR gene in clinical samples. This may greatly help the clinicians develop an appropriate treatment plan.
表皮生长因子受体（EGFR）是一种非小细胞肺癌生物标志物，在此基础上已经开发并应用了几种近患者检测方法，以预测个体患者的治疗反应。现有的 EGFR 突变检测方法既昂贵又费时费力。在本文中，我们报告了一种新型的 EGFR 突变检测系统，该系统基于马赫-曾德尔干涉仪（MZI）传感器和等温固相 DNA 扩增（IDA）技术，称为 MZI-IDA 传感器系统。该系统可以在 30 分钟内提供结果，并且对痕量基因组 DNA（<1 拷贝）具有高灵敏度。此外，该系统能够检测出野生型和突变型细胞 99:1 混合物中的 L858R 突变。在一项初步临床研究中，通过使用非小细胞肺癌患者的组织活检样本，将 MZI-IDA 传感器系统与传统方法（PCR 和直接测序）进行了比较。结果表明，MZI-IDA 传感器系统能够快速准确地检测临床样本中 EGFR 基因的 L858R 突变。这可能极大地帮助临床医生制定适当的治疗计划。
